Bortezomib-Based Induction Is Associated with Superior Outcomes in Light Chain Amyloidosis Patients Treated with Autologous Hematopoietic Cell Transplantation Regardless of Plasma Cell Burden Transplantation and Cellular Therapy March 2021;27(3):264.e1-264.e7
Date
03/01/2021
DOI
10.1016/j.jtct.2020.11.018Scopus ID
2-s2.0-85101183550 (requires institutional sign-in at Scopus site)
11 CitationsAuthor List
Cornell RF, Fraser R, Costa L, Goodman S, Estrada-Merly N, Lee C, Hildebrandt G, Gergis U, Farhadfar N, Freytes CO, Kamble RT, Krem M, Kyle RA, Lazarus HM, Marks DI, Meehan K, Patel SS, Ramanathan M, Olsson RF, Wagner JL, Kumar S, Qazilbash MH, Shah N, Hari P, D'Souza A
Author
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin